Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Blue Cross Blue Shield Association Partner on Precision Medicine Report

NEW YORK (GenomeWeb) – Illumina and the Blue Cross Blue Shield Association will partner in order to develop a better understanding of the state of precision medicine in the US.

The companies said they plan to write a report on the utilization of precision medicine by early 2019 that details the availability and clinical understanding of DNA sequencing technologies, genetic testing, and precision medicine. In addition, the companies also plan to provide educational programs to healthcare providers in areas that they identify as currently having limited access.

"Through our partnership with Illumina, we'll have a better understanding of how precision medicine is being used so we can avoid inequities by ensuring all Americans have access to these lifesaving treatments that are tailored to their individual health needs," Trent Haywood, senior vice president and chief medical officer for the Blue Cross Blue Shield Association, said in a statement.

Phillip Febbo, Illumina's chief medical officer and senior vice president, also noted that "health care providers need to be educated on both the clinical accuracy and usefulness of next generation sequencing."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.